PPLPHARMA
Piramal Finance shares surged sharply today, climbing nearly 12% in midday trading to ₹2,062 after the company posted a strong performance for the March quarter and shared an optimistic growth outlook. Over the past year, the stock has rallied 56%, significantly outperforming the Nifty 50, which has declined 1.1% during the same period. The company’s market capitalisation now exceeds ₹46,000 crore. The upbeat movement follows impressive earnings, with Q4 profit after tax jumping 390% year-on-year to ₹502 crore. For FY26, profit rose 210% to ₹1,506 crore. Assets under management crossed ₹1 lakh crore, marking a 25% annual increase, with the retail segment accounting for 85% of the total portfolio. Meanwhile, the legacy book has been nearly phased out, now making up just 3% of AUM. Asset quality also strengthened, as gross NPAs improved to 2.3%. Operational performance showed notable gains, with net interest margin expanding to 6.5% and the retail operating expense-to-AUM ratio easing to 3.6%, reflecting better efficiency. Looking ahead, the company expects around 25% AUM growth and 50% profit growth in FY27, along with a targeted return on AUM of approximately 2.5%.

















